首页 > 最新文献

Journal of Research in Ayurvedic Sciences最新文献

英文 中文
Efficacy of Ayurveda intervention “Ayuraksha Kit” on COVID-19 incidence and outcomes: A prospective cluster randomized community-based study in India 阿育吠陀干预“Ayuraksha Kit”对COVID-19发病率和结局的疗效:印度一项前瞻性随机社区研究
Pub Date : 2022-10-01 DOI: 10.4103/jras.jras_127_22
Sunita Mata, Kishor Gavali, S. Ota, R. Singhal, Arunabh Tripathi, Seemalata Jain, D. Makhija, Parvathy Nair, P. Nair, P. Aswani, S. Otta, K. Ratha, Dipsunder Sahu, D. Das, H. Singh, Avvaru Sai Prasad, A. Shrivastava, Pallavi Kamble, Laxman W. Bhurke, Saylee Deshmukh, S. Vedi, Swati Sharma, Deepak Sharma, Neelam Singh, Savita Gopod, Chagamreddy Krishna, G. Reddy, S. Sangvikar, Vanmala B Wakode, Emy Surendram, T. Sinimol, K. Kumar, V. Tewari, P. Bharti, G. Bora, Shri Prakash, Rahul D. Ghuse, G. Kumar, Poonam Mohod, V. Negi, C. Antony, S. Paikrao, Anil D. Avhad, Rinky Thakur, M. Shubhashree, R. Naik, S. Asha, K. Devi, Rakesh Rana, B. Sharma, S. Khanduri, Vinod Shahi, Narayanam Srikanth
BACKGROUND: Ayurvedic medicines have been used as preventative care and for managing COVID-19 in India from the early days of the pandemic. This study was conducted to evaluate the effectiveness of the Ayuraksha kit (ARK), a combination of four extensively used Ayurvedic interventions, as prophylactic care against COVID-19. OBJECTIVE: The primary objective was to observe the non-occurrence of COVID-19, and the secondary objective was to observe the changes in the general well-being and manifestation of COVID-19-like symptoms in the participants. MATERIAL AND METHODS: This was a prospective, open-label, multi-center, cluster randomized community-based study conducted from October 2020-March 2021 in India. A total of 153047 participants of either sex, aged 18 - 70 years, living in Scheduled Caste dominated areas of 18 identified states in India, were enrolled. The clusters from where at least one COVID-19 case was identified were randomized and allocated into two groups. In Group-I (n = 1,34,364), Ayuraksha Kit, which contains (Chyawanprash 6 gm once daily; Ayush Kwatha 75 ml once daily; Samshamani Vati 500 mg twice daily and Anu Taila one drop in each nostril twice daily) was administered for one month along with the standard preventive measures for COVID-19. In Group II (n = 18,683), only standard preventive measures for COVID-19 as per the existing guidelines were followed. RESULT: The proportion of participants who did not report having COVID-19 were significantly higher (98.9%)in the ARK group than in the control group (98.1%) after adjusting the history of contact with COVID-19 positive subject/contact with a person having COVID-19 symptoms. The proportion of participants with COVID-19 symptoms was slightly more in the control group. Among the COVID-19-positive cases, symptomatic cases were more in the ARK group, but the incidence of hospitalization (9.8%) was much lesser than that of the control group (12.5%). Improvements in general well-being (appetite, bowel, and sleep quality) were better in the ARK group than in the control group. The medicines in the ARK were well tolerated. CONCLUSIONS: ARK may be used for general well-being and as prophylaxis for preventing COVID-19 infection.
背景:从大流行的早期开始,印度就将阿育吠陀药物用作预防保健和管理COVID-19。本研究旨在评估阿育吠陀药(akuraksha kit, ARK)作为预防COVID-19的有效性,ARK是四种广泛使用的阿育吠陀干预措施的组合。目的:主要目的是观察未发生COVID-19,次要目的是观察参与者总体幸福感的变化和COVID-19样症状的表现。材料和方法:这是一项前瞻性、开放标签、多中心、集群随机社区研究,于2020年10月至2021年3月在印度进行。共有153047名参与者,年龄在18岁至70岁之间,生活在印度18个确定的邦的表列种姓主导地区。至少发现1例COVID-19病例的聚集性病例被随机分为两组。在第一组(n = 1,343,364)中,Ayuraksha Kit含有(Chyawanprash 6 gm,每日一次;Ayush Kwatha 75毫升,每日一次;Samshamani Vati 500毫克,每日两次,Anu Taila每鼻孔一滴,每日两次,服用一个月,同时采取COVID-19的标准预防措施。在第二组(n = 18683)中,仅按照现有指南采取了标准的COVID-19预防措施。结果:在调整了与COVID-19阳性受试者/有COVID-19症状者的接触史后,ARK组未报告感染COVID-19的比例(98.9%)显著高于对照组(98.1%)。在对照组中,出现COVID-19症状的参与者比例略高。在covid -19阳性病例中,ARK组有症状病例较多,但住院率(9.8%)远低于对照组(12.5%)。ARK组在总体健康状况(食欲、肠道和睡眠质量)方面的改善优于对照组。方舟中的药物耐受性良好。结论:ARK可用于一般健康和预防COVID-19感染。
{"title":"Efficacy of Ayurveda intervention “Ayuraksha Kit” on COVID-19 incidence and outcomes: A prospective cluster randomized community-based study in India","authors":"Sunita Mata, Kishor Gavali, S. Ota, R. Singhal, Arunabh Tripathi, Seemalata Jain, D. Makhija, Parvathy Nair, P. Nair, P. Aswani, S. Otta, K. Ratha, Dipsunder Sahu, D. Das, H. Singh, Avvaru Sai Prasad, A. Shrivastava, Pallavi Kamble, Laxman W. Bhurke, Saylee Deshmukh, S. Vedi, Swati Sharma, Deepak Sharma, Neelam Singh, Savita Gopod, Chagamreddy Krishna, G. Reddy, S. Sangvikar, Vanmala B Wakode, Emy Surendram, T. Sinimol, K. Kumar, V. Tewari, P. Bharti, G. Bora, Shri Prakash, Rahul D. Ghuse, G. Kumar, Poonam Mohod, V. Negi, C. Antony, S. Paikrao, Anil D. Avhad, Rinky Thakur, M. Shubhashree, R. Naik, S. Asha, K. Devi, Rakesh Rana, B. Sharma, S. Khanduri, Vinod Shahi, Narayanam Srikanth","doi":"10.4103/jras.jras_127_22","DOIUrl":"https://doi.org/10.4103/jras.jras_127_22","url":null,"abstract":"BACKGROUND: Ayurvedic medicines have been used as preventative care and for managing COVID-19 in India from the early days of the pandemic. This study was conducted to evaluate the effectiveness of the Ayuraksha kit (ARK), a combination of four extensively used Ayurvedic interventions, as prophylactic care against COVID-19. OBJECTIVE: The primary objective was to observe the non-occurrence of COVID-19, and the secondary objective was to observe the changes in the general well-being and manifestation of COVID-19-like symptoms in the participants. MATERIAL AND METHODS: This was a prospective, open-label, multi-center, cluster randomized community-based study conducted from October 2020-March 2021 in India. A total of 153047 participants of either sex, aged 18 - 70 years, living in Scheduled Caste dominated areas of 18 identified states in India, were enrolled. The clusters from where at least one COVID-19 case was identified were randomized and allocated into two groups. In Group-I (n = 1,34,364), Ayuraksha Kit, which contains (Chyawanprash 6 gm once daily; Ayush Kwatha 75 ml once daily; Samshamani Vati 500 mg twice daily and Anu Taila one drop in each nostril twice daily) was administered for one month along with the standard preventive measures for COVID-19. In Group II (n = 18,683), only standard preventive measures for COVID-19 as per the existing guidelines were followed. RESULT: The proportion of participants who did not report having COVID-19 were significantly higher (98.9%)in the ARK group than in the control group (98.1%) after adjusting the history of contact with COVID-19 positive subject/contact with a person having COVID-19 symptoms. The proportion of participants with COVID-19 symptoms was slightly more in the control group. Among the COVID-19-positive cases, symptomatic cases were more in the ARK group, but the incidence of hospitalization (9.8%) was much lesser than that of the control group (12.5%). Improvements in general well-being (appetite, bowel, and sleep quality) were better in the ARK group than in the control group. The medicines in the ARK were well tolerated. CONCLUSIONS: ARK may be used for general well-being and as prophylaxis for preventing COVID-19 infection.","PeriodicalId":394246,"journal":{"name":"Journal of Research in Ayurvedic Sciences","volume":"46 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"132366302","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
An open-label, randomized, exploratory study to evaluate the effect of internal oleation and therapeutic purgation on lipid profile in patients with skin diseases 一项开放标签、随机、探索性研究,旨在评估内油酸和治疗性净化对皮肤病患者血脂的影响
Pub Date : 2022-10-01 DOI: 10.4103/jras.jras_83_21
D. Makhija, V. Deep, S. Krishna rao, Aaditya Shah, R. Patil, Sakshi Sharma, Bharti Gupta, B. Sharma, S. Khanduri, Rakesh Rana, R. Singhal, Narayanam Srikanth
BACKGROUND: In Ayurveda therapeutic principles, internal oleation (IO) is essential before Virechana (purgation therapy). The IO is mainly done using plain or specific medicated ghee according to the disease condition. Virechana is a primarily utilized therapy for treating skin diseases. This pilot study evaluates and compares the effect of IO by using cow ghee (CG) and Mahatiktaka Ghrita (MTG), followed by Virechana, on lipid profiles in individuals suffering from skin diseases but having normal serum lipid levels. MATERIALS AND METHODS: A total of 60 patients were enrolled in this open-label, randomized, multicenter exploratory study and equally divided into two groups. The Ayurveda interventions for IO in groups I and II were CG and MTG, respectively. In both groups, after the completion of 3 to 7 days of IO, Virechana, by using Avipattikar churna (AVC), was done. The effect of the interventions was assessed after completion of IO, and the next day after Virechana, by laboratory investigations such as lipid profile, liver function (LFT) and renal function tests (RFT). Comparative statistical analysis of observations between the baseline, after oleation, and after Virechana was done using statistical software SPSS Version 15.0. RESULTS: A total of 55 participants (27 in group I and 28 in group II) completed the study. After IO and Virechana, changes were reported in the lipid profile, LFT and RFT. All the observed changes are within the standard normal range of the respective laboratory parameters. CONCLUSIONS: To some extent, the IO with CG, MTG, and Virechana therapy can result in clinical changes in LDL, LFT, and RFT within normal limits. As per the Ayurveda concepts, Sansarjana Karma is a must after Virechana for complete recovery. Therefore, further research on changes in lipid profile after IO and Virechana following Sansarjana Karma is required.
背景:在阿育吠陀的治疗原则中,在Virechana(净化治疗)之前,内部油液(IO)是必不可少的。IO主要根据疾病情况使用普通或特定的药物酥油。Virechana主要用于治疗皮肤病。本初步研究通过使用牛油(CG)和maatiktaka Ghrita (MTG),然后是Virechana来评估和比较IO对患有皮肤病但血清脂质水平正常的个体的脂质特征的影响。材料与方法:这项开放标签、随机、多中心的探索性研究共纳入60例患者,平均分为两组。I组和II组IO的阿育吠陀干预措施分别为CG和MTG。两组在IO结束3 ~ 7天后,用AVC (Avipattikar churna)进行Virechana。干预措施的效果在IO完成后和Virechana后第二天通过血脂、肝功能(LFT)和肾功能测试(RFT)等实验室调查进行评估。使用SPSS Version 15.0统计软件对基线、油分后和Virechana后的观察值进行比较统计分析。结果:共有55名参与者(I组27名,II组28名)完成了研究。在IO和Virechana后,脂质谱、LFT和RFT发生了变化。所有观察到的变化都在各自实验室参数的标准正常范围内。结论:在一定程度上,使用CG、MTG和Virechana治疗的IO可使LDL、LFT和RFT在正常范围内发生临床变化。根据阿育吠陀的概念,轮回是Virechana之后完全恢复所必须的。因此,需要进一步研究IO和Virechana后的脂质变化。
{"title":"An open-label, randomized, exploratory study to evaluate the effect of internal oleation and therapeutic purgation on lipid profile in patients with skin diseases","authors":"D. Makhija, V. Deep, S. Krishna rao, Aaditya Shah, R. Patil, Sakshi Sharma, Bharti Gupta, B. Sharma, S. Khanduri, Rakesh Rana, R. Singhal, Narayanam Srikanth","doi":"10.4103/jras.jras_83_21","DOIUrl":"https://doi.org/10.4103/jras.jras_83_21","url":null,"abstract":"BACKGROUND: In Ayurveda therapeutic principles, internal oleation (IO) is essential before Virechana (purgation therapy). The IO is mainly done using plain or specific medicated ghee according to the disease condition. Virechana is a primarily utilized therapy for treating skin diseases. This pilot study evaluates and compares the effect of IO by using cow ghee (CG) and Mahatiktaka Ghrita (MTG), followed by Virechana, on lipid profiles in individuals suffering from skin diseases but having normal serum lipid levels. MATERIALS AND METHODS: A total of 60 patients were enrolled in this open-label, randomized, multicenter exploratory study and equally divided into two groups. The Ayurveda interventions for IO in groups I and II were CG and MTG, respectively. In both groups, after the completion of 3 to 7 days of IO, Virechana, by using Avipattikar churna (AVC), was done. The effect of the interventions was assessed after completion of IO, and the next day after Virechana, by laboratory investigations such as lipid profile, liver function (LFT) and renal function tests (RFT). Comparative statistical analysis of observations between the baseline, after oleation, and after Virechana was done using statistical software SPSS Version 15.0. RESULTS: A total of 55 participants (27 in group I and 28 in group II) completed the study. After IO and Virechana, changes were reported in the lipid profile, LFT and RFT. All the observed changes are within the standard normal range of the respective laboratory parameters. CONCLUSIONS: To some extent, the IO with CG, MTG, and Virechana therapy can result in clinical changes in LDL, LFT, and RFT within normal limits. As per the Ayurveda concepts, Sansarjana Karma is a must after Virechana for complete recovery. Therefore, further research on changes in lipid profile after IO and Virechana following Sansarjana Karma is required.","PeriodicalId":394246,"journal":{"name":"Journal of Research in Ayurvedic Sciences","volume":"64 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131730419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prophylactic effect of Ayurveda interventions in prevention of COVID 19 in selected containment zones of Delhi: A prospective open label community based study 阿育吠陀干预措施在德里选定隔离区预防COVID - 19的预防作用:一项前瞻性开放标签社区研究
Pub Date : 2022-10-01 DOI: 10.4103/jras.jras_124_22
B. Rao, B. Yadav, M. Sharma, Sophia Jameela, Rakesh Rana, R. Singhal, B. Sharma, S. Khanduri, D. Makhija, Bharti Gupta, Adarsh Kumar, S. N., K. Dhiman, Field Investigators
BACKGROUND: The exponential rise of cases and associated morbidity and mortality has managed to make COVID-19 a serious threat. Minimising the transmission of disease by prevention and control strategy forms the core-pillar of response. Ayurveda with its holistic approach can potentially promote disease prophylaxis both at the individual as well as community levels. This clinical study was executed in a community set-up to explore the potential of Ayurvedic interventions in COVID-19 prophylaxis. MATERIALS AND METHODS: The study was conducted as an open label community based study in six selected containment zones of Delhi on 9200 individuals with an objective to record the incidence of COVID-19 in these areas. The selected Ayurvedic Interventions (Ashwagandha, Maha Sudarshan Ghan Vati, Samshamani Vati) were distributed in the dose of two tablets of 250 mg each twice daily after food with lukewarm water for a period of one month. Onset of any COVID-19 related clinical symptoms, patient satisfaction in general health parameters and incidence of ADR/AE were taken as outcome measures. RESULTS: 9010 participants were recruited with mean age of 37.9 years. A total of 12 participants (0.17%) were reported positive during the intervention period, among 279 who underwent testing (because of contact tracing or symptoms). Participants who were devoid of any symptoms throughout the trial period were 98.8%. Statistically significant improvement was observed in parameters of general well-being at the end of study period. CONCLUSION: Ayurveda interventions demonstrated potential as a safe prophylactic measure against COVID 19 with comparatively good compliance and minimal adverse effects.
背景:病例及相关发病率和死亡率呈指数级上升,已使COVID-19成为严重威胁。通过预防和控制战略尽量减少疾病传播是应对工作的核心支柱。阿育吠陀的整体方法可以潜在地促进个人和社区层面的疾病预防。该临床研究是在一个社区机构中进行的,旨在探索阿育吠陀干预在COVID-19预防中的潜力。材料和方法:该研究是一项基于开放标签社区的研究,在德里六个选定的控制区内对9200人进行研究,目的是记录这些地区的COVID-19发病率。选定的阿育吠陀干预措施(Ashwagandha, Maha Sudarshan Ghan Vati, Samshamani Vati)每天两次,每次250毫克,在用温水进食后分发,为期一个月。以新冠肺炎相关临床症状的出现、患者对一般健康参数的满意度和不良反应/不良反应发生率作为结局指标。结果:9010名参与者被招募,平均年龄37.9岁。在干预期间,在279名接受检测(由于接触者追踪或症状)的参与者中,共有12人(0.17%)报告呈阳性。在整个试验期间没有任何症状的参与者占98.8%。在研究期结束时,在总体幸福感参数中观察到统计学上显著的改善。结论:阿育吠陀干预措施作为一种安全的预防COVID - 19的措施具有较好的依从性和最小的不良反应。
{"title":"Prophylactic effect of Ayurveda interventions in prevention of COVID 19 in selected containment zones of Delhi: A prospective open label community based study","authors":"B. Rao, B. Yadav, M. Sharma, Sophia Jameela, Rakesh Rana, R. Singhal, B. Sharma, S. Khanduri, D. Makhija, Bharti Gupta, Adarsh Kumar, S. N., K. Dhiman, Field Investigators","doi":"10.4103/jras.jras_124_22","DOIUrl":"https://doi.org/10.4103/jras.jras_124_22","url":null,"abstract":"BACKGROUND: The exponential rise of cases and associated morbidity and mortality has managed to make COVID-19 a serious threat. Minimising the transmission of disease by prevention and control strategy forms the core-pillar of response. Ayurveda with its holistic approach can potentially promote disease prophylaxis both at the individual as well as community levels. This clinical study was executed in a community set-up to explore the potential of Ayurvedic interventions in COVID-19 prophylaxis. MATERIALS AND METHODS: The study was conducted as an open label community based study in six selected containment zones of Delhi on 9200 individuals with an objective to record the incidence of COVID-19 in these areas. The selected Ayurvedic Interventions (Ashwagandha, Maha Sudarshan Ghan Vati, Samshamani Vati) were distributed in the dose of two tablets of 250 mg each twice daily after food with lukewarm water for a period of one month. Onset of any COVID-19 related clinical symptoms, patient satisfaction in general health parameters and incidence of ADR/AE were taken as outcome measures. RESULTS: 9010 participants were recruited with mean age of 37.9 years. A total of 12 participants (0.17%) were reported positive during the intervention period, among 279 who underwent testing (because of contact tracing or symptoms). Participants who were devoid of any symptoms throughout the trial period were 98.8%. Statistically significant improvement was observed in parameters of general well-being at the end of study period. CONCLUSION: Ayurveda interventions demonstrated potential as a safe prophylactic measure against COVID 19 with comparatively good compliance and minimal adverse effects.","PeriodicalId":394246,"journal":{"name":"Journal of Research in Ayurvedic Sciences","volume":"28 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"127907891","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy of Ayurveda formulations, Panchamrit Lauha Guggulu and Panchguna Taila in the management of Cervical Spondylosis (Greevagraha): A prospective single-arm clinical trial 阿育吠陀配方、Panchamrit Lauha Guggulu和Panchguna Taila治疗颈椎病(Greevagraha)的疗效:一项前瞻性单臂临床试验
Pub Date : 2022-10-01 DOI: 10.4103/jras.jras_102_21
V. Negi, Renu Singh, Anubha Chandla, O. Sharma, SurinderKumar Sharma, Rakesh Rana, R. Singhal, B. Sharma, S. Khanduri, Adarsh Kumar, Narayanam Srikanth
BACKGROUND: Cervical spondylosis (CS) is a degenerative disease of intervertebral discs with the formation of osteophytes in the cervical vertebrae. Based on the similarity in symptoms such as intermittent neck and shoulder pain, pain and stiffness radiating to the shoulder or occipital region, restricted neck movements, numbness, and weakness in arms, hands, and fingers, CS can be correlated with Greevagraha—a disease of the neck narrated in Ayurveda. In Ayurveda, the formulations Panchamrit Lauha Guggulu (PLG) and Panchguna Taila (PGT) have been narrated in treating musculoskeletal disorders. OBJECTIVE: The objective of the study was to evaluate the clinical efficacy and safety of PLG and PGT in the management of CS. MATERIALS AND METHODS: It was a prospective, single-arm, open-label clinical study. A total of 63 patients aged 30–60 years diagnosed with CS have been treated with PLG 250 mg twice a day orally with lukewarm water after food and an external application of PGT at the neck region. The total duration of the treatment was 12 weeks, with a follow-up every 2 weeks and a post treatment follow-up after 2 weeks of the treatment. The outcome measures include change in Northwick Park Neck Pain Questionnaire (NPNPQ) score, Visual Analog Scale (VAS) score for cardinal features, SF-36 (research and development [RAND]) Health Survey Score, and incidence of adverse events (if any). RESULTS: At baseline, X-ray findings of all participants (100%) had degenerative changes at different levels of cervical vertebrae; however, posttreatment X-ray findings (on the 84th day of study) showed normal X-ray findings in eight participants (5.04%). A significant reduction in the total VAS score (P < 0.001) was observed on day 84 and day 98. The mean NPNPQ score reduced significantly (P < 0.0001), and a highly significant change was observed in the SF-36 Health Survey Score (P < 0.0001). No adverse events were reported during the study period. CONCLUSIONS: PLG and PGT have shown promising outcomes in managing CS and were also safe. However, randomized control trials with adequate sample size, standard care as control, and a longer follow-up may be planned to establish the findings of this preliminary study.
背景:颈椎病(CS)是一种椎间盘退行性疾病,伴有颈椎骨赘形成。基于症状的相似性,如间歇性颈部和肩部疼痛,疼痛和僵硬辐射到肩部或枕区,颈部运动受限,麻木,手臂,手和手指无力,CS可以与阿育吠陀中描述的颈部疾病greevagraha相关。在阿育吠陀,配方Panchamrit Lauha Guggulu (PLG)和Panchguna Taila (PGT)已叙述在治疗肌肉骨骼疾病。目的:评价PLG和PGT治疗CS的临床疗效和安全性。材料和方法:这是一项前瞻性、单臂、开放标签临床研究。共63例年龄30-60岁的CS患者接受PLG 250mg,每日2次,餐后用温水口服,并在颈部外敷PGT。治疗总时间为12周,每2周随访一次,治疗2周后随访一次。结局指标包括诺斯威克公园颈部疼痛问卷(NPNPQ)评分、主要特征视觉模拟量表(VAS)评分、SF-36(研发[RAND])健康调查评分和不良事件发生率(如果有)的变化。结果:在基线时,所有参与者(100%)的x线表现在不同水平的颈椎有退行性改变;然而,治疗后x线表现(研究第84天)显示8名参与者(5.04%)的x线表现正常。在第84天和第98天观察到VAS总评分显著降低(P < 0.001)。NPNPQ平均评分显著降低(P < 0.0001), SF-36健康调查评分变化极显著(P < 0.0001)。研究期间无不良事件报告。结论:PLG和PGT在治疗CS方面显示出良好的效果,并且是安全的。然而,有足够样本量的随机对照试验,作为对照的标准护理,以及更长的随访,可能会计划建立这个初步研究的结果。
{"title":"Efficacy of Ayurveda formulations, Panchamrit Lauha Guggulu and Panchguna Taila in the management of Cervical Spondylosis (Greevagraha): A prospective single-arm clinical trial","authors":"V. Negi, Renu Singh, Anubha Chandla, O. Sharma, SurinderKumar Sharma, Rakesh Rana, R. Singhal, B. Sharma, S. Khanduri, Adarsh Kumar, Narayanam Srikanth","doi":"10.4103/jras.jras_102_21","DOIUrl":"https://doi.org/10.4103/jras.jras_102_21","url":null,"abstract":"BACKGROUND: Cervical spondylosis (CS) is a degenerative disease of intervertebral discs with the formation of osteophytes in the cervical vertebrae. Based on the similarity in symptoms such as intermittent neck and shoulder pain, pain and stiffness radiating to the shoulder or occipital region, restricted neck movements, numbness, and weakness in arms, hands, and fingers, CS can be correlated with Greevagraha—a disease of the neck narrated in Ayurveda. In Ayurveda, the formulations Panchamrit Lauha Guggulu (PLG) and Panchguna Taila (PGT) have been narrated in treating musculoskeletal disorders. OBJECTIVE: The objective of the study was to evaluate the clinical efficacy and safety of PLG and PGT in the management of CS. MATERIALS AND METHODS: It was a prospective, single-arm, open-label clinical study. A total of 63 patients aged 30–60 years diagnosed with CS have been treated with PLG 250 mg twice a day orally with lukewarm water after food and an external application of PGT at the neck region. The total duration of the treatment was 12 weeks, with a follow-up every 2 weeks and a post treatment follow-up after 2 weeks of the treatment. The outcome measures include change in Northwick Park Neck Pain Questionnaire (NPNPQ) score, Visual Analog Scale (VAS) score for cardinal features, SF-36 (research and development [RAND]) Health Survey Score, and incidence of adverse events (if any). RESULTS: At baseline, X-ray findings of all participants (100%) had degenerative changes at different levels of cervical vertebrae; however, posttreatment X-ray findings (on the 84th day of study) showed normal X-ray findings in eight participants (5.04%). A significant reduction in the total VAS score (P < 0.001) was observed on day 84 and day 98. The mean NPNPQ score reduced significantly (P < 0.0001), and a highly significant change was observed in the SF-36 Health Survey Score (P < 0.0001). No adverse events were reported during the study period. CONCLUSIONS: PLG and PGT have shown promising outcomes in managing CS and were also safe. However, randomized control trials with adequate sample size, standard care as control, and a longer follow-up may be planned to establish the findings of this preliminary study.","PeriodicalId":394246,"journal":{"name":"Journal of Research in Ayurvedic Sciences","volume":"32 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124033091","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy and safety of Ayush AGT gel-based cream in superficial external wounds: Study protocol of an open-label multicenter interventional single-arm trial Ayush AGT凝胶霜治疗浅表外伤的疗效和安全性:一项开放标签多中心介入单臂试验的研究方案
Pub Date : 2022-10-01 DOI: 10.4103/jras.jras_112_22
A. Rai, S. Khanduri, Sumeet Goel, Maheshwar Thugutla, H. Panigrahi, Avvaru Sai Prasad, Anil D. Avhad, R. Singhal, Rakesh Rana, B. Chandrasekhararao, Narayanam Srikanth
BACKGROUND: Traditional medicine has been extensively used to manage skin wounds since ancient times. Central Council for Research in Ayurvedic Sciences has developed a coded herbal formulation, Ayush AGT gel-based cream, through a systematic drug development process for managing superficial skin wounds. OBJECTIVE: This clinical study is designed to determine the clinical efficacy and safety of Ayush AGT gel-based cream in healing superficial external wounds. MATERIALS AND METHODS: This open-label, multicenter, prospective, interventional single-arm trial is being conducted at three peripheral institutes of the Central Council for Research in Ayurvedic Sciences, Ministry of Ayush, Government of India viz. Central Ayurveda Research Institute, New Delhi, and Regional Ayurveda Research Institutes at Ahmedabad and Vijayawada, India. A total of 30 participants will be enrolled in the study from each of the three study sites. Patients of any sex aged 18–60 years with superficial external wounds requiring dressing and solitary wounds not less than 2.5 cm in diameter will be considered for enrollment in the study. The enrolled participants will be managed by the topical application of Ayush AGT gel-based cream on the wound bed once daily, followed by bandaging with the sterile material for four weeks. The outcome measures are time to complete re-epithelialization of the wound, incidence of wound infection, pain during the change of dressing (assessed through visual analog scale), incidence of blistering, and adverse events. DISCUSSION: Ayurveda interventions have been found effective in wound healing in routine clinical practice as well as in published experimental and clinical studies. Ethno-medicine practices also utilize different medicinal plants to manage skin wounds. Several patents on herbal interventions for wound healing have also been granted. However, clinical research to explore the standard wound management for superficial external wounds is not common. So, it is expected that the outcomes of this study will provide a significant lead in the search for safe and effective management options for skin wounds.
背景:传统医学自古以来就被广泛用于皮肤伤口的治疗。阿育吠陀科学研究中央委员会通过系统的药物开发过程,开发了一种编码草药配方,即阿尤什AGT凝胶霜,用于治疗浅表皮肤伤口。目的:本临床研究旨在确定阿尤什AGT凝胶型乳膏治疗浅表外创面的临床疗效和安全性。材料和方法:这项开放标签、多中心、前瞻性、干预性单臂试验正在印度阿育吠陀科学中央研究委员会、阿尤什部、印度政府的三个外围研究所进行,即新德里的阿育吠陀中央研究所和印度艾哈迈达巴德和维杰亚瓦达的阿育吠陀地区研究所。来自三个研究地点的30名参与者将被纳入研究。年龄在18-60岁的任何性别,需要包扎的浅表外创面且孤立创面直径不小于2.5 cm的患者将被考虑纳入研究。入选的参与者将通过每天一次在伤口床上局部应用Ayush AGT凝胶霜进行管理,然后用无菌材料包扎四周。结果测量是伤口完成再上皮化的时间,伤口感染的发生率,更换敷料期间的疼痛(通过视觉模拟量表评估),起泡的发生率和不良事件。讨论:阿育吠陀干预已被发现有效的伤口愈合在常规临床实践以及发表的实验和临床研究。民族医学实践也利用不同的药用植物来治疗皮肤伤口。一些草药干预伤口愈合的专利也被授予。然而,探讨浅表外伤标准创面处理的临床研究并不多见。因此,本研究的结果有望为寻找安全有效的皮肤伤口治疗方案提供重要的指导。
{"title":"Efficacy and safety of Ayush AGT gel-based cream in superficial external wounds: Study protocol of an open-label multicenter interventional single-arm trial","authors":"A. Rai, S. Khanduri, Sumeet Goel, Maheshwar Thugutla, H. Panigrahi, Avvaru Sai Prasad, Anil D. Avhad, R. Singhal, Rakesh Rana, B. Chandrasekhararao, Narayanam Srikanth","doi":"10.4103/jras.jras_112_22","DOIUrl":"https://doi.org/10.4103/jras.jras_112_22","url":null,"abstract":"BACKGROUND: Traditional medicine has been extensively used to manage skin wounds since ancient times. Central Council for Research in Ayurvedic Sciences has developed a coded herbal formulation, Ayush AGT gel-based cream, through a systematic drug development process for managing superficial skin wounds. OBJECTIVE: This clinical study is designed to determine the clinical efficacy and safety of Ayush AGT gel-based cream in healing superficial external wounds. MATERIALS AND METHODS: This open-label, multicenter, prospective, interventional single-arm trial is being conducted at three peripheral institutes of the Central Council for Research in Ayurvedic Sciences, Ministry of Ayush, Government of India viz. Central Ayurveda Research Institute, New Delhi, and Regional Ayurveda Research Institutes at Ahmedabad and Vijayawada, India. A total of 30 participants will be enrolled in the study from each of the three study sites. Patients of any sex aged 18–60 years with superficial external wounds requiring dressing and solitary wounds not less than 2.5 cm in diameter will be considered for enrollment in the study. The enrolled participants will be managed by the topical application of Ayush AGT gel-based cream on the wound bed once daily, followed by bandaging with the sterile material for four weeks. The outcome measures are time to complete re-epithelialization of the wound, incidence of wound infection, pain during the change of dressing (assessed through visual analog scale), incidence of blistering, and adverse events. DISCUSSION: Ayurveda interventions have been found effective in wound healing in routine clinical practice as well as in published experimental and clinical studies. Ethno-medicine practices also utilize different medicinal plants to manage skin wounds. Several patents on herbal interventions for wound healing have also been granted. However, clinical research to explore the standard wound management for superficial external wounds is not common. So, it is expected that the outcomes of this study will provide a significant lead in the search for safe and effective management options for skin wounds.","PeriodicalId":394246,"journal":{"name":"Journal of Research in Ayurvedic Sciences","volume":"39 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"121976387","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
"Chikitsa Sutra": A ready reckoner of treatment guidelines catering to rationalization of Ayurvedic ideology “奇基察经”:一个现成的治疗指南的计算迎合合理化阿育吠陀意识形态
Pub Date : 2022-10-01 DOI: 10.4103/jras.jras_167_22
Rabina Acharya
{"title":"\"Chikitsa Sutra\": A ready reckoner of treatment guidelines catering to rationalization of Ayurvedic ideology","authors":"Rabina Acharya","doi":"10.4103/jras.jras_167_22","DOIUrl":"https://doi.org/10.4103/jras.jras_167_22","url":null,"abstract":"","PeriodicalId":394246,"journal":{"name":"Journal of Research in Ayurvedic Sciences","volume":"78 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131724185","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Knowledge, attitudes, and practice of Triphala in the community: An exploratory cross-sectional survey study Triphala在社区中的知识、态度和实践:一项探索性横断面调查研究
Pub Date : 2022-10-01 DOI: 10.4103/jras.jras_55_22
V. Mali, Anupama Krishnan, P. Mali, Ketki Wagh, Sikha Lekharu, P. Gupte
BACKGROUND: Codified and noncodified information about Ayurveda practices and formulations is available and transmitted as science or folk claims. Triphala, a well-researched Ayurveda formulation, lacks studies reporting community perception regarding its usage. This study explores Triphala’s knowledge, attitude, and practice in the community. MATERIALS AND METHODS: This exploratory cross-sectional study involving 806 residents of Pune, New Delhi, Guwahati, Kottakkal, and rural areas of Rajkot was undertaken to evaluate Triphala’s knowledge, attitude, and practice in the community. A pretested and structured questionnaire addressing Triphala’s knowledge, attitude, and practice was administered through Google forms or a personal interview method. Data were managed and analyzed by SPSS 20.0, and descriptive statistics were generated. RESULTS: A total of 30% of participants demonstrated good knowledge, and 42% demonstrated positive attitude. A total of 41.84% of respondents knew the ingredients of Triphala, 68% knew its use in constipation, 26% in health maintenance, and 22.2% in weight loss. Also, powdered dosage form (93.6%) is used predominantly through the oral route with lukewarm water (94.1%) as a vehicle. Around half of the respondents have previously used Triphala for various health conditions. The knowledge regarding the proportion of Triphala ingredients, and other formulations containing Triphala, was less at all sites. A good number of people (38.9%) are ready to consume Triphala for health maintenance. The rural area had a lower response rate compared with the urban but with similar response patterns for most domains. CONCLUSIONS: A substantial proportion of people in the general population knew the ingredients of Triphala, its use in various health conditions, route of administration, adjuvants, and cost-effectiveness. A good number of people showed readiness for the consumption of Triphala daily. However, the research component of Triphala has not sufficiently percolated. Hence, empowering the public on the utilization aspects and research evidence of Triphala would propagate the evidence-based practice of Ayurveda for scientific sustainability.
背景:关于阿育吠陀实践和配方的编纂和非编纂的信息是可用的,并作为科学或民间声称传播。Triphala是一种经过充分研究的阿育吠陀配方,缺乏关于其用法的社区认知的研究。本研究探讨了Triphala在社区中的知识、态度和实践。材料和方法:本探索性横断面研究涉及浦那、新德里、古瓦哈提、kottakal和拉杰科特农村地区的806名居民,以评估Triphala在社区中的知识、态度和实践。通过谷歌表格或个人访谈法,对Triphala的知识、态度和实践进行了预先测试和结构化的问卷调查。数据采用SPSS 20.0进行管理和分析,生成描述性统计。结果:30%的参与者表现出良好的知识,42%的参与者表现出积极的态度。41.84%的受访者知道Triphala的成分,68%的受访者知道其用于便秘,26%的受访者知道其用于保健,22.2%的受访者知道其用于减肥。此外,粉末状剂型(93.6%)主要通过口服途径使用,以温水(94.1%)作为载体。大约一半的答复者以前曾使用Triphala治疗各种健康状况。关于Triphala成分比例的知识,以及其他含有Triphala的配方,在所有地点都较少。很多人(38.9%)准备为了保健而消费Triphala。农村地区的响应率低于城市地区,但大多数领域的响应模式相似。结论:普通人群中有相当比例的人知道Triphala的成分、在各种健康状况下的使用、给药途径、佐剂和成本-效果。许多人表示愿意每天食用特里法拉。然而,Triphala的研究成分还没有充分渗透。因此,授权公众了解Triphala的使用方面和研究证据将宣传阿育吠陀的循证实践,以实现科学的可持续性。
{"title":"Knowledge, attitudes, and practice of Triphala in the community: An exploratory cross-sectional survey study","authors":"V. Mali, Anupama Krishnan, P. Mali, Ketki Wagh, Sikha Lekharu, P. Gupte","doi":"10.4103/jras.jras_55_22","DOIUrl":"https://doi.org/10.4103/jras.jras_55_22","url":null,"abstract":"BACKGROUND: Codified and noncodified information about Ayurveda practices and formulations is available and transmitted as science or folk claims. Triphala, a well-researched Ayurveda formulation, lacks studies reporting community perception regarding its usage. This study explores Triphala’s knowledge, attitude, and practice in the community. MATERIALS AND METHODS: This exploratory cross-sectional study involving 806 residents of Pune, New Delhi, Guwahati, Kottakkal, and rural areas of Rajkot was undertaken to evaluate Triphala’s knowledge, attitude, and practice in the community. A pretested and structured questionnaire addressing Triphala’s knowledge, attitude, and practice was administered through Google forms or a personal interview method. Data were managed and analyzed by SPSS 20.0, and descriptive statistics were generated. RESULTS: A total of 30% of participants demonstrated good knowledge, and 42% demonstrated positive attitude. A total of 41.84% of respondents knew the ingredients of Triphala, 68% knew its use in constipation, 26% in health maintenance, and 22.2% in weight loss. Also, powdered dosage form (93.6%) is used predominantly through the oral route with lukewarm water (94.1%) as a vehicle. Around half of the respondents have previously used Triphala for various health conditions. The knowledge regarding the proportion of Triphala ingredients, and other formulations containing Triphala, was less at all sites. A good number of people (38.9%) are ready to consume Triphala for health maintenance. The rural area had a lower response rate compared with the urban but with similar response patterns for most domains. CONCLUSIONS: A substantial proportion of people in the general population knew the ingredients of Triphala, its use in various health conditions, route of administration, adjuvants, and cost-effectiveness. A good number of people showed readiness for the consumption of Triphala daily. However, the research component of Triphala has not sufficiently percolated. Hence, empowering the public on the utilization aspects and research evidence of Triphala would propagate the evidence-based practice of Ayurveda for scientific sustainability.","PeriodicalId":394246,"journal":{"name":"Journal of Research in Ayurvedic Sciences","volume":"93 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"133153388","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Therapeutic evaluation of Rasnadi Gutika and Chandrakala Lepa in Janusandhigata Vata (osteoarthritis knee): A single-arm prospective multicenter clinical study Rasnadi Gutika和Chandrakala Lepa治疗膝骨性关节炎的疗效评价:单臂前瞻性多中心临床研究
Pub Date : 2022-04-01 DOI: 10.4103/jras.jras_38_21
Banamali Das, Sanjay Singh, S. Meher, Alok Kumar Srivastav, S. Ota, Rakesh Rana, Richa Singhl, B. Sharma, S. Khanduri, Adarsh Kumar, M. Rao, Narayanam Srikanth
BACKGROUND: Sandhivata [osteoarthritis (OA)] is one of the Vata Vyadhi, which causes much suffering for a prolonged period. The cause of Sandhivata in Ayurveda is attributed to improper diet, lifestyle, and old age, leading to aggravation of Vata, and is associated with slow and steady decline in tissue quality and function. The disease specific symptoms of Sandhigata vata are very similar to that of OA. Treatment in OA is targeted for reviving joint function through halting the disease pathogenesis and promotion of joint health and vitality. OBJECTIVE: The objective of this study was to assess the clinical efficacy of Rasnadi Gutika (RG) and Chandrakala Lepa (CKL) in the management of Janusandhigata Vata [osteoarthritis knee (OA knee)]. MATERIALS AND METHODS: The study was conducted at two peripheral institutes of the Central Council for Research in Ayurvedic Sciences, viz., Central Ayurveda Research Institute, Bhubaneswar, Odisha and Regional Ayurveda Research Institute, Lucknow, Uttar Pradesh. A total of 120 patients between the age of 40 and 75 years suffering from primary OA knee joint were treated with RG and CKL. The duration of the therapy was 12 weeks, and follow-up was done on the 14th, 28th, 42nd, 56th, 70th, and 84th days. RG was administered orally in the dose of 1 g twice daily with lukewarm water, and CKL 10 g was applied locally twice daily for 12 weeks. Parameters such as chief complaints of the disease, viz., joint pain on movement, joint pain at rest, restricted joint, crepitus, swollen joint, stiffness, and bony enlargement; total WOMAC score; and quality of life through WHO QOL BREF score were assessed before and after the administration of therapy. RESULTS: The WOMAC score, the key outcome measure, showed statistically significant improvement (P = 0.001) on the 84th day of follow-up. Improvement was noted in all areas, including pain, stiffness, and physical functioning. The physical health, physiological and social relationships, and environmental areas of the WHO QOL BREF score for quality of life were also significantly influenced (P = 0.0001). No adverse drug reactions or adverse events were reported during the trial period. CONCLUSION: Oral administration of RG and external application of CKL are effective for the management of OA knee. However, further clinical study with sufficient sample size may be required to revalidate this study’s findings.
背景:骨关节炎(OA)是Vata Vyadhi中的一种,它会导致长期的痛苦。在阿育吠陀中,sanghivata的病因归因于不适当的饮食、生活方式和老年,导致Vata的恶化,并与组织质量和功能的缓慢而稳定的下降有关。该疾病的具体症状与OA非常相似。骨性关节炎的治疗目标是通过阻止疾病的发病机制和促进关节的健康和活力来恢复关节功能。目的:本研究的目的是评估Rasnadi Gutika (RG)和Chandrakala Lepa (CKL)治疗膝骨性关节炎(OA膝)的临床疗效。材料和方法:该研究是在阿育吠陀科学中央研究委员会的两个外围研究所进行的,即位于奥里萨邦布巴内斯瓦尔的中央阿育吠陀研究所和位于北方邦勒克瑙的地区阿育吠陀研究所。120例40 ~ 75岁原发性OA膝关节患者采用RG联合CKL治疗。疗程为12周,随访时间为第14、28、42、56、70、84天。RG 1 g / 2次/温开水口服,CKL 10 g / 2次/局部给药,连续12周。参数如疾病的主症,即运动时的关节痛、休息时的关节痛、受限的关节、肌痛、关节肿胀、僵硬和骨肿大;WOMAC总分;并通过WHO QOL BREF评分评估治疗前后患者的生活质量。结果:关键结局指标WOMAC评分在随访第84天有统计学显著改善(P = 0.001)。所有方面都有改善,包括疼痛、僵硬和身体功能。WHO生活质量QOL BREF评分的身体健康、生理和社会关系以及环境领域也受到显著影响(P = 0.0001)。试验期间未发生药物不良反应或不良事件。结论:口服RG和外敷CKL是治疗膝关节炎的有效方法。然而,可能需要进一步的临床研究和足够的样本量来重新验证本研究的结果。
{"title":"Therapeutic evaluation of Rasnadi Gutika and Chandrakala Lepa in Janusandhigata Vata (osteoarthritis knee): A single-arm prospective multicenter clinical study","authors":"Banamali Das, Sanjay Singh, S. Meher, Alok Kumar Srivastav, S. Ota, Rakesh Rana, Richa Singhl, B. Sharma, S. Khanduri, Adarsh Kumar, M. Rao, Narayanam Srikanth","doi":"10.4103/jras.jras_38_21","DOIUrl":"https://doi.org/10.4103/jras.jras_38_21","url":null,"abstract":"BACKGROUND: Sandhivata [osteoarthritis (OA)] is one of the Vata Vyadhi, which causes much suffering for a prolonged period. The cause of Sandhivata in Ayurveda is attributed to improper diet, lifestyle, and old age, leading to aggravation of Vata, and is associated with slow and steady decline in tissue quality and function. The disease specific symptoms of Sandhigata vata are very similar to that of OA. Treatment in OA is targeted for reviving joint function through halting the disease pathogenesis and promotion of joint health and vitality. OBJECTIVE: The objective of this study was to assess the clinical efficacy of Rasnadi Gutika (RG) and Chandrakala Lepa (CKL) in the management of Janusandhigata Vata [osteoarthritis knee (OA knee)]. MATERIALS AND METHODS: The study was conducted at two peripheral institutes of the Central Council for Research in Ayurvedic Sciences, viz., Central Ayurveda Research Institute, Bhubaneswar, Odisha and Regional Ayurveda Research Institute, Lucknow, Uttar Pradesh. A total of 120 patients between the age of 40 and 75 years suffering from primary OA knee joint were treated with RG and CKL. The duration of the therapy was 12 weeks, and follow-up was done on the 14th, 28th, 42nd, 56th, 70th, and 84th days. RG was administered orally in the dose of 1 g twice daily with lukewarm water, and CKL 10 g was applied locally twice daily for 12 weeks. Parameters such as chief complaints of the disease, viz., joint pain on movement, joint pain at rest, restricted joint, crepitus, swollen joint, stiffness, and bony enlargement; total WOMAC score; and quality of life through WHO QOL BREF score were assessed before and after the administration of therapy. RESULTS: The WOMAC score, the key outcome measure, showed statistically significant improvement (P = 0.001) on the 84th day of follow-up. Improvement was noted in all areas, including pain, stiffness, and physical functioning. The physical health, physiological and social relationships, and environmental areas of the WHO QOL BREF score for quality of life were also significantly influenced (P = 0.0001). No adverse drug reactions or adverse events were reported during the trial period. CONCLUSION: Oral administration of RG and external application of CKL are effective for the management of OA knee. However, further clinical study with sufficient sample size may be required to revalidate this study’s findings.","PeriodicalId":394246,"journal":{"name":"Journal of Research in Ayurvedic Sciences","volume":"315 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124293617","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Developing research ecosystem in Ayurveda institutions and inculcating research culture among Ayurveda professionals—Need of the hour 在阿育吠陀机构中发展研究生态系统,在阿育吠陀专业人士中灌输研究文化——当前的需求
Pub Date : 2022-04-01 DOI: 10.4103/jras.jras_85_22
B. Prasad
{"title":"Developing research ecosystem in Ayurveda institutions and inculcating research culture among Ayurveda professionals—Need of the hour","authors":"B. Prasad","doi":"10.4103/jras.jras_85_22","DOIUrl":"https://doi.org/10.4103/jras.jras_85_22","url":null,"abstract":"","PeriodicalId":394246,"journal":{"name":"Journal of Research in Ayurvedic Sciences","volume":"278 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"121716321","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy of Ksharasutra prepared through automated machine and manual process in fistula-in-ano: A study protocol for a double-blind, randomized controlled trial 自动机器和手工工艺制备Ksharasutra治疗瘘管的疗效:一项双盲、随机对照试验的研究方案
Pub Date : 2022-04-01 DOI: 10.4103/jras.jras_95_22
A. Rai, B. Yadav, H. Panigrahi, R. Singhal, B. Chandrasekhararao, Rakesh Rana, Narayanam Srikanth
BACKGROUND: The manufacturing process of Ksharasutra is still predominantly manual, even in the current era. It inherently leads to small-scale production and restricted availability of this effective treatment. CCRAS has developed a prototype of an automated machine to manufacture the Ksharasutra on a large scale. OBJECTIVE: This clinical study will investigate the safety and efficacy of the Ksharasutra prepared through the automated machine and compare its efficacy with the manually prepared Ksharasutra. MATERIALS AND METHODS: This study is a double-blind, randomized controlled, parallel-group trial being conducted at the Central Ayurveda Research Institute, New Delhi. A total of 100 participants will be enrolled in the study. Individuals of any sex aged 18–60 years and diagnosed with fistula-in-ano complaining of perianal discharge, pain, tenderness, itching, and induration will be enrolled in the trial. The enrolled participants will be managed by the automated machine-prepared Ksharasutra in the trial group and the manually prepared Ksharasutra in the control group. The Ksharasutra will be changed every week till the fistula tract is completely cut off. The outcome measures include the change in the quality of life (assessed through the SF-36 questionnaire), unit cutting time of the fistula tract, the proportion of participants having complete healing of the fistula tract, and the incidence of adverse events. DISCUSSION: The conventional surgical treatment of fistula-in-ano is associated with a significant recurrence rate and a high risk of impaired anal continence. Compared with conventional treatment, Ksharasutra therapy is simple, cost-effective, and associated with minor post-operative care, minimal complications, and a low recurrence rate. However, small-scale manufacturing due to manual preparation, non-uniformity of techniques involved in the manufacturing of Ksharasutra, and so on limits the availability and quality of this therapy. Awareness regarding the benefits of Ksharasutra therapy and availability of surgeons experienced in this procedure can play a significant role in improving the accessibility of this para-surgical technique. TRIAL REGISTRATION: CTRI/2021/12/038414, dated 3 Dec. 2021
背景:即使在当今时代,Ksharasutra的制造过程仍然主要是手工的。它必然导致小规模生产和这种有效治疗的可得性受到限制。CCRAS开发了一种自动化机器的原型,用于大规模生产《经》。目的:本临床研究将探讨自动器械制备经的安全性和有效性,并将其与手工制备经的疗效进行比较。材料和方法:本研究是一项双盲、随机对照、平行组试验,在新德里的中央阿育吠陀研究所进行。总共有100名参与者将被纳入这项研究。年龄在18-60岁的任何性别的被诊断为肛门瘘管的个体,并抱怨肛周分泌物、疼痛、压痛、瘙痒和硬化,将被纳入试验。被招募的参与者将由试验组的自动机器准备的经书和对照组的手动准备的经书进行管理。每周更换经,直到瘘道完全切断。结局指标包括生活质量的改变(通过SF-36问卷评估)、瘘道单位切割时间、参与者瘘道完全愈合的比例和不良事件的发生率。讨论:传统的肛管手术治疗与显著的复发率和肛门失禁受损的高风险相关。与传统治疗相比,按摩疗法简单、经济、术后护理少、并发症少、复发率低。然而,由于手工制备的小规模生产,制造Ksharasutra所涉及的技术不均匀,等等限制了这种疗法的可用性和质量。认识到穴拉陀疗法的益处以及在此过程中经验丰富的外科医生的可用性,可以在提高这种手术辅助技术的可及性方面发挥重要作用。试验注册:CTRI/2021/12/038414,日期为2021年12月3日
{"title":"Efficacy of Ksharasutra prepared through automated machine and manual process in fistula-in-ano: A study protocol for a double-blind, randomized controlled trial","authors":"A. Rai, B. Yadav, H. Panigrahi, R. Singhal, B. Chandrasekhararao, Rakesh Rana, Narayanam Srikanth","doi":"10.4103/jras.jras_95_22","DOIUrl":"https://doi.org/10.4103/jras.jras_95_22","url":null,"abstract":"BACKGROUND: The manufacturing process of Ksharasutra is still predominantly manual, even in the current era. It inherently leads to small-scale production and restricted availability of this effective treatment. CCRAS has developed a prototype of an automated machine to manufacture the Ksharasutra on a large scale. OBJECTIVE: This clinical study will investigate the safety and efficacy of the Ksharasutra prepared through the automated machine and compare its efficacy with the manually prepared Ksharasutra. MATERIALS AND METHODS: This study is a double-blind, randomized controlled, parallel-group trial being conducted at the Central Ayurveda Research Institute, New Delhi. A total of 100 participants will be enrolled in the study. Individuals of any sex aged 18–60 years and diagnosed with fistula-in-ano complaining of perianal discharge, pain, tenderness, itching, and induration will be enrolled in the trial. The enrolled participants will be managed by the automated machine-prepared Ksharasutra in the trial group and the manually prepared Ksharasutra in the control group. The Ksharasutra will be changed every week till the fistula tract is completely cut off. The outcome measures include the change in the quality of life (assessed through the SF-36 questionnaire), unit cutting time of the fistula tract, the proportion of participants having complete healing of the fistula tract, and the incidence of adverse events. DISCUSSION: The conventional surgical treatment of fistula-in-ano is associated with a significant recurrence rate and a high risk of impaired anal continence. Compared with conventional treatment, Ksharasutra therapy is simple, cost-effective, and associated with minor post-operative care, minimal complications, and a low recurrence rate. However, small-scale manufacturing due to manual preparation, non-uniformity of techniques involved in the manufacturing of Ksharasutra, and so on limits the availability and quality of this therapy. Awareness regarding the benefits of Ksharasutra therapy and availability of surgeons experienced in this procedure can play a significant role in improving the accessibility of this para-surgical technique. TRIAL REGISTRATION: CTRI/2021/12/038414, dated 3 Dec. 2021","PeriodicalId":394246,"journal":{"name":"Journal of Research in Ayurvedic Sciences","volume":"74 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130365553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Research in Ayurvedic Sciences
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1